NASDAQ:SNBP Sun BioPharma (SNBP) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free SNBP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.60▼$0.6950-Day Range$3.45▼$4.5052-Week Range$2.37▼$10.00Volume92,549 shsAverage Volume26,926 shsMarket Capitalization$6.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Sun BioPharma alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Sun BioPharmaSun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota.Read More Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> SNBP Stock News HeadlinesMarch 27, 2024 | bbc.co.ukTips for staying safe in the sunMarch 10, 2024 | msn.comSun Pharma recalls 55,000 bottles of generic drug from US market; here's whyMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 10, 2024 | msn.comSun Pharma recalls 55,000 bottles of generic drug from US market due to manufacturing norms violationJanuary 31, 2024 | msn.comSun Pharma Q3 Results: Net profit rises 16.5% to Rs 2,523.8 croreDecember 17, 2023 | msn.comSun Pharma, Lupin recall drugs in US on manufacturing woesDecember 17, 2023 | msn.comSun Pharma, Lupin recall drugs in US market: USFDANovember 1, 2023 | msn.comSun Pharma Q2 results: Profit rises 5% to Rs 2,376 crore YoY; revenue up 11%March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.November 1, 2023 | reuters.comIndia's top drugmaker Sun Pharma beats Q2 profit viewOctober 27, 2023 | uk.investing.comSun Pharmaceutical Industries Ltd. (SUN)October 8, 2023 | msn.comSun Pharma, Aurobindo recall drugs from US marketOctober 8, 2023 | msn.comSun Pharma, Aurobindo recall drugs from USOctober 4, 2023 | marketwatch.comBiofrontera Says Sun Pharmaceutical Alleging Breach of Contract In LawsuitSeptember 21, 2023 | benzinga.comDebiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat CancersSeptember 16, 2023 | msn.comLIC Reduces Stake In Sun Pharma From 5.023% To 3.012%August 28, 2023 | msn.comSun Pharma aims to spend 7-8% of sales on R&DAugust 17, 2023 | marketwatch.comSun Pharmaceutical Industries rises Wednesday, outperforms marketAugust 1, 2023 | marketwatch.comSun Pharmaceutical Industries rises Tuesday, outperforms marketJuly 30, 2023 | msn.comSun Pharma, Alembic recall drugs in US market due to manufacturing issuesJuly 6, 2023 | marketwatch.comSun Pharmaceutical Industries underperforms Thursday when compared to competitorsJune 26, 2023 | msn.comSun Pharma gets approval from Health Canada for acne drug ABSORICA LDJune 26, 2023 | markets.businessinsider.comSun Pharma Canada: Health Canada Approves ABSORICA LD - Quick FactsJune 24, 2023 | msn.comSun Pharma Announces Data From First-in-Human Phase 1 Studies Of GL0034 At American Diabetes AssociationJune 22, 2023 | marketwatch.comSun Pharmaceutical Industries falls Thursday, still outperforms marketJune 19, 2023 | msn.comSun Pharma Announces Health Canada Approval Of WINLEVI For Topical Treatment Of AcneJune 15, 2023 | marketwatch.comSun Pharmaceutical Industries rises Thursday, outperforms marketSee More Headlines Receive SNBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sun BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2020Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SNBP CUSIPN/A CIKN/A Webwww.sunbiopharma.com Phone952-479-1196FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares9,649,000Free FloatN/AMarket Cap$6.46 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Michael T. Cullen Jr. (Age 74)Co-Founder & Exec. Chairman Comp: $282.35kMs. Susan Horvath (Age 61)VP of Fin., CFO, Sec. & Treasurer Comp: $220.31kDr. Jennifer K. Simpson (Age 52)CEO, Pres & Director Dr. Thomas X. NeenanCo-Founder & Chief Scientific OfficerMs. Tammy GroeneVP of OperationsDr. Suzanne Gagnon (Age 63)Chief Medical Officer & Director More ExecutivesKey CompetitorsGT BiopharmaNASDAQ:GTBPPulmatrixNASDAQ:PULMSoligenixNASDAQ:SNGXOragenicsNYSE:OGENKinetaNASDAQ:KAView All Competitors SNBP Stock Analysis - Frequently Asked Questions How were Sun BioPharma's earnings last quarter? Sun BioPharma, Inc. (NASDAQ:SNBP) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.09. What other stocks do shareholders of Sun BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sun BioPharma investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cumberland Pharmaceuticals (CPIX), Entasis Therapeutics (ETTX), Evelo Biosciences (EVLO), Kaleido Biosciences (KLDO). This page (NASDAQ:SNBP) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sun BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.